Is Abos stock a buy or sell?
[Read more...] According to 4 analysts, the average rating for ABOS stock is "Buy." The 12-month stock price forecast is 24.00, which is an increase of 369.67% from the latest price.
Is acumen pharmaceuticals (Abos) stock a buy?
The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia. [Read more...] According to 4 analysts, the average rating for ABOS stock is "Buy."
Who buys ababos stock?
ABOS stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio, and New York State Common Retirement Fund. Company insiders that have bought Acumen Pharmaceuticals stock in the last two years include John A Stalfort III, Nathan B Fountain, Paul B Manning, and Sands Capital Global Venture F.
What was the price of abosus on Jan 11 2022?
ABOSU.S.: Nasdaq Acumen Pharmaceuticals Inc. WatchlistCreateABOSAlert ABOSUS After Hours Last Updated: Jan 11, 2022 4:00 p.m. ESTDelayed quote $5.64 0.000.00% After Hours Volume:5 Close Chg Chg % $5.64
Is ABOS a good stock?
Out of 6 analysts, 4 (66.67%) are recommending ABOS as a Strong Buy, 2 (33.33%) are recommending ABOS as a Buy, 0 (0%) are recommending ABOS as a Hold, 0 (0%) are recommending ABOS as a Sell, and 0 (0%) are recommending ABOS as a Strong Sell.
Is Acumen Pharmaceuticals a good stock to buy?
Acumen Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Is Acumen Pharmaceuticals publicly traded?
Acumen raised $160 million in its initial public offering Thursday morning after selling 10 million shares at the high end of its price range, and shares were skyrocketing 35% as of 1:01 p.m. ET.
Is ABOS stock a buy right now?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last year. There are currently 4 buy ratings...
Will Acumen Pharmaceuticals' stock price go up in 2022?
4 brokerages have issued 1-year price targets for Acumen Pharmaceuticals' shares. Their forecasts range from $14.00 to $27.00. On average, they pre...
How has Acumen Pharmaceuticals' stock performed in 2022?
Acumen Pharmaceuticals' stock was trading at $6.76 at the beginning of 2022. Since then, ABOS stock has decreased by 41.7% and is now trading at $3...
When is Acumen Pharmaceuticals' next earnings date?
Acumen Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast fo...
How were Acumen Pharmaceuticals' earnings last quarter?
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) issued its quarterly earnings results on Sunday, November, 14th. The company reported ($0.10) earnings p...
Who are Acumen Pharmaceuticals' key executives?
Acumen Pharmaceuticals' management team includes the following people: Mr. Daniel J. O'Connell M.B.A. , CEO, Pres & Director (Age 52, Pay $336k)...
Who are some of Acumen Pharmaceuticals' key competitors?
Some companies that are related to Acumen Pharmaceuticals include Sangamo Therapeutics (SGMO) , Cullinan Oncology (CGEM) , Coherus BioSciences (...
When did Acumen Pharmaceuticals IPO?
(ABOS) raised $125 million in an initial public offering on Thursday, July 1st 2021. The company issued 8,333,333 shares at $14.00-$16.00 per share.
What is Acumen Pharmaceuticals' stock symbol?
Acumen Pharmaceuticals trades on the NASDAQ under the ticker symbol "ABOS."
What is Acumen Pharmaceuticals' ticker symbol?
When will Acumen Pharmaceuticals release its earnings?
Acumen Pharmaceuticals trades on the NASDAQ under the ticker symbol "ABOS."
